Regeneron is back with long-term follow-up for its LAG-3 inhibitor and PD-1 inhibitor combo in advanced melanoma, phase 1 findings that have prompted the company to launch four phase 3 programs with the intent to rival Bristol Myers Squibb’s approved Opdualag.

Immune checkpoint inhibitors are the superheroes of cancer therapy. Drugs like Bristol Myers Squibb’s Opdivo and Merck’s Keytruda are among the most profitable in the world—Keytruda pulled in $25 billion last year, making it the bestselling drug of 2023. But every good superhero needs a sidekick.

Medtronic is bringing on a new chief medical officer for its digital and robotics teams, who it described as one of the top five robotic surgeons in the U.S.

Neurocrine Biosciences’ schizophrenia program pivot has failed. The biotech was unable to replicate the cognition signal it saw in an earlier midphase study, prompting it to stop development of luvadaxistat.

After Apple previewed the technology earlier this week, the FDA has now given the green light to the hearing aid features of its premium AirPods.

Cancer company Oncternal Therapeutics is folding all its clinical trials and laying off staff, turning its energy toward exploring strategic alternatives such as asset sales, a merger or acquisition.

Just four months after Sanofi bet $80 million in upfront cash on Fulcrum Therapeutics’ losmapimod, the program has ended in a phase 3 failure.

The European Organization for Research and Treatment of Cancer (EORTC), a network of 3,800 members across 50 countries, is extending a partnership with Medidata for another four years, according to a Sept. 11 release.

After an initial defeat against the biggest barrier to mRNA flu vaccines—namely, B strains of influenza—GSK has returned with a reformulated candidate that has delivered the goods in the all-important population of older adults.

Shortly after a positive data drop for Eli Lilly’s efsitora alfa, the Indianapolis-based company is again padding the case for its weekly insulin prospect.